Skip to main content

PAPEL DE LAS ACTIVIDADES ANTI-PROLIFERATIVAS Y ANTI-INFLAMATORIAS DEL RECEPTOR NUCLEAR LXR EN EL CRECIMIENTO TUMORAL Y LA METASTASIS

SAF2010-14989

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2010
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pharmacologic activation of LXR alters the expression profile of tumor-associated macrophages and the abundance of regulatory T cells in the tumor microenvironment

  • Carbó, José María
  • León, Theresa E.
  • Font-Díaz, Joan
  • Rosa, Juan V. de la
  • Castrillo, Antonio
  • Picard, Felix R.
  • Staudenraus, Daniel
  • Huber, Magdalena
  • Cedó, Lídia
  • Escolà-Gil, Joan Carles
  • Campos, Lucía
  • Bakiri, Latifa
  • Wagner, Erwin F.
  • Caelles, Carme
  • Stratmann, Thomas
  • Ginderachter, Jo A. Van
  • Valledor, Annabel F.
Liver X receptors (LXR) are transcription factors from the nuclear receptor family that are activated by oxysterols and synthetic high-affinity agonists. In this study, we assessed the antitumor effects of synthetic LXR agonist TO901317 in a murine model of syngeneic Lewis Lung carcinoma. Treatment with TO901317 inhibited tumor growth in wild-type, but not in LXR-deficient mice, indicating that the antitumor effects of the agonist depends on functional LXR activity in host cells. Pharmacologic activation of the LXR pathway reduced the intratumoral abundance of regulatory T cells (Treg) and the expression of the Treg-attracting chemokine Ccl17 by MHCIIhigh tumor-associated macrophages (TAM). Moreover, gene expression profiling indicated a broad negative impact of the LXR agonist on other mechanisms used by TAM for the maintenance of an immunosuppressive environment. In studies exploring the macrophage response to GM-CSF or IL4, activated LXR repressed IRF4 expression, resulting in subsequent downregulation of IRF4-dependent genes including Ccl17. Taken together, this work reveals the combined actions of the LXR pathway in the control of TAM responses that contribute to the antitumoral effects of pharmacologic LXR activation. Moreover, these data provide new insights for the development of novel therapeutic options for the treatment of cancer., This work was supported by the following grants: Spanish Ministry of Economy and Competitivity (MINECO) grants SAF2017-89510-R and SAF2014-57856-P [to A.F. Valledor and C. Caelles; SAF2014-56819-R to A. Castrillo; SAF2017-90604-REDT and SAF2015-71878-REDT to the NuRCaMeIn network (to A.F. Valledor, C. Caelles, and A. Castrillo); Spanish Ministry of Science and Innovation (MICINN) grants SAF2011-23402 and SAF2010-14989 (to A.F. Valledor); Fundacio La Marato de TV3 grant 080930 (to A.F. Valledor); grants DFG HU 1824/5-1, 1824/7-1, and 1824/9-1 (to M. Huber); the European Cooperation in Science and Technology (COST) Action BM1404 Mye-EUNITER (http://www.mye-euniter. eu/; to A.F. Valledor, J.A. Van Ginderachter); and Instituto de Salud Carlos III and FEDER “Una manera de hacer Europa” grant FIS 16/00139 (to J.C. Escola-Gil). CIBERDEM is an Instituto de Salud Carlos III project. J.M. C received a fellowship from the University of Barcelona (APIF) and J. Font-Díaz received a fellowship from the Spanish Ministry of Science, Innovation and Universities (FPI, PRE2018-085579).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism

  • Matalonga, Jonathan
  • Glaria, Estibaliz
  • Bresque, Mariana|||0000-0002-4570-3629
  • Escande, Carlos|||0000-0002-9611-0903
  • Carbó, José María|||0000-0001-8301-5360
  • Kiefer, Kerstin
  • Vicente, Ruben
  • León, Theresa E.
  • Beceiro, Susana
  • Pascual-García, Mónica|||0000-0002-9768-0641
  • Serret, Joan
  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Morón-Ros, Samantha|||0000-0002-6205-2442
  • Riera, Antoni|||0000-0001-7142-7675
  • Paytubi, Sonia
  • Antonio Juarez, Antonio
  • Sotillo, Fernando
  • Lindbom, Lennart
  • Caelles, Carme
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Sancho, Jaime
  • Castrillo, Antonio|||0000-0002-2057-2159
  • Chini, Eduardo N.
  • Valledor, Annabel F.|||0000-0003-4232-2633
Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of nonopsonized Salmonella to infect macrophages.remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bonemarrow- derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway.